Health Care · Ophthalmic Goods · NYSE · CIK 1860742 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $16.20Day −2.47%Mkt cap $5.8B1Y +10.6%Off 52W high −14.4%Vol (1Y) 30.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,058 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 61.9% growth |
| Short interest1.1% of sh out |
| Days to cover10.3d |
| 13F net flow (QoQ)−0.10% |
| Top-10 13F concentration67.1% |
| Next report (est.)2026-10-28 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$5.32B |
| Earnings (TTM)-$171.0M |
| ROE−5.6% |
| Net margin−7.1% |
| ROIC0.8% |
| Debt / equity0.78× |
| YTD−5.2% |
| 1Y+10.6% |
| 3Y−18.5% |
| Since incept. (ann.)−4.9% |
Total return through 2026-07-29 · series begins 2022-05-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)30.8% |
| Ann. volatility (3Y)38.6% |
| Sharpe (1Y)0.53 |
| Sharpe (3Y)0.02 |
| Max drawdown (1Y)−20.1% |
| Max drawdown (3Y)−47.9% |
| Beta (3Y vs SPY)0.95 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| DEUTSCHE BANK AG\ | 3.5M | $56M | 0.99% | +2.3% |
| ICAHN CARL C | 3.5M | $56M | 0.98% | +0.0% |
| OAKTREE CAPITAL MANAGEMENT LP | 3.4M | $54M | 0.95% | +0.0% |
| D. E. Shaw & Co., Inc. | 3.2M | $50M | 0.88% | +10.7% |
| GOLDENTREE ASSET MANAGEMENT LP | 2.7M | $42M | 0.74% | +0.0% |
| Silver Point Capital L.P. | 2.2M | $36M | 0.63% | −12.5% |
| Davidson Kempner Capital Management LP | 2.2M | $35M | 0.62% | +13.4% |
| CASPIAN CAPITAL LP | 2.0M | $32M | 0.56% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | −$0.20 | — | $1.24B | +9.4% |
| 2025-12-31 | 2026-02-18 | — | — | $1.41B | +9.8% |
| 2025-09-30 | 2025-10-29 | −$0.08 | −900.0% | $1.28B | +7.1% |
| 2025-06-30 | 2025-07-30 | −$0.18 | — | $1.28B | +5.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Vision Care 57% · Pharmaceuticals 25% · Surgical 18%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA9.45× |
| Sales growth 3Y10.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
